Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

The goal of this clinical trial is to learn if neoadjuvant intravesical instillation of mitomycin C combined with en-bloc surgery works to treat high-risk non-muscle-invasive bladder cancer (NMIBC) patients. It will also learn about the safety of neoadjuvant intravesical instillation of mitomycin C. The main questions it aims to answer are: Does neoadjuvant intravesical instillation of mitomycin C heighten the 1-year recurrence-free survival (RFS) rate for high-risk non-muscle-invasive bladder cancer (NMIBC) patients? What medical problems do participants have when taking neoadjuvant intraves

Trial Details

NCT ID
NCT06696794
Phase
PHASE3
Sponsor
Shaogang Wang
Status
RECRUITING
Cancer Type
Urothelial Carcinoma Bladder Cancer
Interventions
  • Mitomycin C (MMC)
  • Normal Saline (Placebo)
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667
  • Wuhan, Hubei, China|30.58333,114.26667
  • Xiangyang, Hubei, China|32.0422,112.14479

Key Eligibility Criteria

  • Voluntarily sign an informed consent form, understand the study and are willing and able to follow and complete all trial procedures
  • Gender is not limited, age between 18 to 75 years old (inclusive of boundary values)
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Previously confirmed non-muscle-invasive bladder cancer by imaging and pathology

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Urothelial Carcinoma Bladder Cancer Trials on Trialify →